@BigChodu They actually are pretty much a 100m market cap when you factor in the dilution from warrants sold that would raise an additional 100m from the last deal.
Oculis $OCS I am not sure what Roche and Novartis are waiting for. Company has three successful small Phase 2 trials which are de risked to work in larger Phase3s. In two multi billion eye disease areas - DME and dry eye - plus rare optic neuro asset that can work in MS!
@contrariandesk Thesis is simple in that I expect all 3 programs likely are approved drugs based on successful Phase 2 data and valuation nowhere near reflects Phase3 success probability and commercial opportunity which can reach into multi billions. Go $OCS of course have a position 😀
@Biomaven Compare to $700M on plant spent by Agilent recently for older phosphoramatide chemistry. Enzymatic is needed for the wave of high prevalence RNAi drugs coming to market (LPa INHBE Hypertension …) $CDXS partnered with Bachem $LLY and play on RNAi as future $ALNY $ARWR $IONS $WVE
@Biomaven On a 2 to 3 year investment horizon an investment in Codexis should be quite profitable if they can achieve GMP manufacturing of siRNA using the new enzymatic synthesis process. $CDXS. Think better, faster, cheaper easier to scale up first plant only $25M in capex.
@buysidebio Codexis $CDXS is leading the way with enzymatic synthesis of oligonucelotides and siRNA per multiple presentations at last few TIDES conferences and has partnered on technology with Bachem/Lilly $LLY and other CDMOs and is one to watch for the coming siRNA 💥 boom
@midwit_capital It should be a good 2nd half 2025 for $PSNL as it expects Medicare approval and reimbursement in 2 indications with a 3rd likely to follow in 2026. The colon cancer CRC data presented this year was also a nice surprise and Personalis can be used across all cancers.
@unusual_whales Tempus AI $TEM if they were smart would quickly raise $1 Billion at this valuation and put in a bid to buy all of Personalis $PSNL whose WGS Whole Genome Sequencing technology they will need to dominate MRD tumor informed testing for years to come.
@WagsCapitalLLC Both virus Iran and eplontersen are approved and successful in ATTR-PN while tafamadiz did not. I would bet on silencers over stabilizers here. Long $ALNY and $IONS and short $BBIO is the way to go
@2000ManBioTech@Pyrazoleurea@adamfeuerstein Why must we all agree that we’ve reached the end of days for biomedical innovation? That’s indeed what we disagree on. It’s what people thought 20 years ago and many times since. Every time market drops, someone assumes it’s the end. Always wrong to bet against progress.
@PeterKolchinsky@Pyrazoleurea@adamfeuerstein But surely we are knowingly using our past reputation to also extract large personal fortunes for investing in what we must all agree at this point are diminished expected return projects. We are potentially tarnishing our own image and the entire industry.
@PeterKolchinsky@Pyrazoleurea@adamfeuerstein Then being handed more and more sums of money to invest… to fund eventually lesser quality ideas does my reputation and image suffer or should it? Was it worth raising the extra capital. Surely no other investors need participate. We can say we are funding science
@The_Real_Fly@BioLunacyJG Why is this screwed up? Looks like the government is NOT being racist by getting a public health and safety message out to a minority community that has a different culture and traditional language. This is us resinsible and caring leadership 👍😀
34 Followers 360 Following@DairyLandDiv
Passionate investor detailing my investing journey. I am using the knowledge I gain to help others learn, grow & develop a passion for investing.
271 Followers 4K FollowingEx-soldier and hedge fund manager; now investor, advisor, podcaster, and public speaker. «If you think like everyone else, you'll perform like everyone else».
404 Followers 7K FollowingAksjeinvestor med hovedfokus pà selskaper som betaler kvartalsvis- og ärlig utbytte. Folg min reise mot okonomisk frihet pa https://t.co/6W7BmUnC38
210 Followers 332 Followingbiotech news and sideline chirps - not investment advice. Running the biochirp (s)ub(s)tack linked below. Building early stage biotech from 9-5.
526 Followers 2K FollowingNews Portal for BioTech, MedTech, and HealthTech News - Don't Waste your time trying to find Live, Curated, and Searchable News on BioTech + More!
171 Followers 356 FollowingBiotech stock trader, EV (5 in total) owner since 2013, installed solar arrays on 3 homes, fan of alternative energy, flora & fauna.
3K Followers 229 FollowingLong / short trading with objective of beating $SPY in good times and protecting capital in bad. NOT financial advice. Subscribe for free at https://t.co/ojgKxYXKt6
2K Followers 263 Followingmd candidate @yalemed, writing at https://t.co/gffDMMDkZR, prev @delfidiagnostic @ibmresearch and math @johnshopkins. Views my own.
2K Followers 2K Followingjust a silly cat in this sillicate world.
checkout https://t.co/8PlA91jinY and https://t.co/EdCm1AhuuC . strive to be kind. #pahalamaxxing | buy https://t.co/yvYE4T6UjP
655K Followers 19K FollowingJoin me weekdays at WFJB AM 1776 (parody account) MAGA🇺🇸 With Great Power, Comes Great Responsibility 💥Dinesh, Ryan Fournier. No DMs No Porn.
5K Followers 922 FollowingLong special distressed situs, with enormous risk/upside and down. Each position has dedicated hours of diligence, sometimes days. *Posts not investment advice.
504 Followers 580 Following#ㄴIFㅌ 🇰🇷, 🇺🇸 Born in Seoul, Ohio-raised. Founder @__BLUE__ROOM__, Partner, ID EST, Chair, Economic Club of Colorado, Trustee Emeritus, MCA Denver
23K Followers 10 FollowingThe most comprehensive health check.
2,000+ locations. 160+ lab tests.
Advanced imaging. Private AI chat.
Starting at $1/day. Check your health.